VIVUS, Inc. (VVUS) Announces Positive Recommendation From CHMP Supporting Avanafil Approval in Europe
4/26/2013 11:01:14 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MOUNTAIN VIEW, Calif., April 26, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for avanafil (SPEDRA™) for the treatment of erectile dysfunction (ED) in the European Union. The CHMP recommendation will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union. A final decision from the EC regarding the SPEDRA Marketing Authorization Application (MAA) is expected within approximately two months.
Help employers find you! Check out all the jobs and post your resume.